GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?
<p dir="ltr">Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as groundbreaking therapeutic agents in managing a spectrum of <u>metabolic disorders</u>, demonstrating remarkable efficacy across multiple organ systems and disease states. These compounds ar...
Saved in:
| Main Author: | Abdelilah Arredouani (10914455) (author) |
|---|---|
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploring Glucagon‐Like Peptide‐1 Receptor Agonists Usage Among Non‐Diabetic Healthcare Providers: A Cross‐Sectional Multi‐Country Study
by: Abdulqadir J. Nashwan (11659453)
Published: (2025) -
Liraglutide for idiopathic intracranial hypertension: a real‐world propensity score‐matched study
by: Ahmed Y. Azzam (14267391)
Published: (2025) -
The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome
by: Alison J. Dawson (18175003)
Published: (2019) -
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
by: Shahad Sabaawi Ibrahim (21842273)
Published: (2024) -
Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid Metabolism
by: Khaoula Errafii (10914446)
Published: (2022)